Daily Stock Opinions and Ratings

Opinions

Jim Cramer - Mad MoneyWalgreen Boots AllianceWBADON'T BUYSep 06, 2023

Cracks appeared here when their CEO suddenly left. Also, are plagued by theft (shrinkage) like much of retail. Only the name brand is a positive.

Jim Cramer - Mad Money

Unknown

Unlock Rating

$22.64

Stock price when the opinion was issued

$12.05

As of Aug 27, 2025. Market Open.

specialty stores

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

They need to cut their dividend and present a plan.

DON'T BUY

It reports Thursday. The company is in disarray and can't see a way out of this mess. For instance, they have located two stocks a few blocks apart. in one city. They have no idea what they're doing.

DON'T BUY

Since 2014 - stock has not performed well.
Much prefers CVS.
Pharmacy sales impacted after Covid-19.
Recession will also be tough on business.
Dividend yield fairly safe.
Better names for growth and value.

SELL

Down 20% in the last 6 months. Their problem is that they are the ultimate brick-and-mortar company at a time when Amazon is crushing their performance.

DON'T BUY

They report Tuesday. Very worried. Not sure if their buy of Summit Health can give their shares a boost. Have been a poor performer among retailers with decent balance sheets. He needs to hear them speak about theft. Buying stuff there is discouraging because it's under lock and key. It's easier to buy from Amazon.

Unspecified

It is not that bad but he prefers and owns CVS in the space.

BUY

Recent pullback good for long term investors.
Recessionary environment is good for business (cheaper products).
Strong assets with 8500 locations in USA.
Excellent brand with strong track record.

HOLD

He prefers CVS which has more dynamic growth in many health businesses, though if you already own WBA you don't need to sell it. WBA has a strong balance and the dividend is safe. Better stocks in healthcare elsewhere.

DON'T BUY

A serial underperformer, but the new CEO is making WBA more of a care-focused operation with clinics and in-home services. He's optimistic, but frankly it's easier to order some items from Amazon and not a WBA store.

DON'T BUY

Among the worst Dow performers in Q3 Down 17%. Pays a 6% yield. He expected more from them given the Covid booster shot business. Trades at 6.3x earnings. That tell him they gained little market share during the pandemic unlike CVS. They lack a strategy to compete with Amazon; people buy consumer staples from Amazon instead. Walgreen stores are short of staff, which effects service.

BUY

Tough for years with decrease in consumer traffic during the pandemic. Likes the company and healthy dividend. Will see recovery as pandemic eases. Stable business that is good for long term investor.

HOLD

Has since sold shares. Doesn't think company is headed in the right direction. Peer group analysis indicating company not as strong as competitors. Better names to own within the sector.

DON'T BUY

They're in a competitive market. Exposure to the UK is more dire a situation than the US. She isn't buying this.

DON'T BUY

It has had problematic headlines. It has settled a lawsuit but another is coming. It should have done well but it has too many issues.

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management